Navigation Links
Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008
Date:1/21/2009

Quarterly Reports Use Market Intelligence and Competitive Analysis from Thomson Reuters to Highlight Developments in the Global Pharmaceutical Industry

PHILADELPHIA and LONDON, Jan. 21 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of three Pharma Matters reports covering the time period July - September 2008. The quarterly Pharma Matters series covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping System(SM).

The Ones to Watch - A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q3 2008, the top five most promising drugs launched or receiving approval were:

    DRUG          DISEASE                     COMPANY

    Zeftera(TM)   Complicated skin and soft   Basilea Pharmaceutica
                  tissue infections

    Firazyr(R)    Hereditary angioedema       Jerini

    Bridion(R)    Reversal of muscle          Schering-Plough
                  relaxants

    Cleviprex(TM) Perioperative               The Medicines Company
                  hypertension

    Xarelto(R)    Venous thromboembolic       Bayer/Ortho-McNeil
                  events                      Pharmaceutical

More analysis, as well as information on drugs entering clinical Phases I, II and III are available in the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008totw_q3.pdf.

Movers and Shakers - This report covers the US generics industry using data and analysis from Newport Horizon Premium, the critical product targeting the global business development system. Analysis from the Q3 2008 report includes:

  • The pharmaceutical marketplace continued to demonstrate volatility, and the pace of patent challenges showed no sign of slackening in the third quarter of 2008.
  • During the third quarter of 2008, final approvals were issued on only 77 'A'-rated ANDAs, plummeting down from 142 the quarter before. First-time approvals of generic products by the FDA also dropped from 11 to 8 this quarter.
  • Seven new products (three combination products and four single active ingredient products) were subjected to paragraph IV challenges for the first time in Q3 2008, identical to the previous quarter.
  • Indian groups were in first place in terms of ANDA approvals during Q3 2008. Twelve India-based corporations received a total of 17 final ANDA approvals.
  • In the same time period, 11 US-based companies received a total of 15 approvals, putting the U.S. in second place for this quarter.
  • Mylan of the U.S. and Boehringer Ingelheim of Germany received the most final ANDA approvals (seven each).

To learn more about companies making their mark on the U.S. generics market, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008ms_q3.pdf

Who is Making the Biggest Splash? - A Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System. In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the 15 listed organizations that have made the biggest impact as the leading sources of information on medical research from July - September 2008 are:

  1. Novartis
  2. Bristol-Meyers Squibb
  3. Eli Lilly
  4. Pfizer
  5. AstraZeneca

To see the complete list, as well as analysis and methodology, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008wmtbs_q3.pdf

To sign up for the Thomson Reuters Pharma Matters series of publications visit: http://scientific.thomsonreuters.com/forms/matters/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Scientific Predicts Nobel Laureates
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
6. Thomson Acquires Prous Science
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. Thomson Scientific Ranks Australian Universities and Research Institutes
9. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
10. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
11. Thomson Healthcare Launches Application That Assesses Physician Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... ... May 29, 2017 , ... A New York high tech ... month test of the effectiveness of Artificial Intelligence (AI) in helping nudge men forward ... game,’ said Wayne Hartrick, President of the Canadian Men’s Health Foundation (CMHF), whose mission ...
(Date:5/28/2017)... ... May 28, 2017 , ... ... proud to announce that Sheldon K. Cho, MD, has joined its Winter Haven ... specialty that concentrates on minimally invasive techniques to treat and manage many types ...
(Date:5/27/2017)... ... 2017 , ... From May 21-23, hearing healthcare professionals gained a competitive edge ... the Marriott Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s technology ... healthcare providers to help them stay ahead in the industry. At the event, EarQ ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... new educational seminar to focus on current legislative activity and the latest regulatory ... at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for ... applications. “We are thrilled to partner with Cupron® to provide customers with ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
(Date:5/12/2017)... May 12, 2017  The China and Canada ... that consumes less water, energy and detergent, and features a powerful ... LaughingU, a shoebox-sized washing machine that washes and sanitizes women,s panties ... ... is compact, and does not require an external water inlet. ...
(Date:5/10/2017)... -- Radiology has become the number one diagnostic tool ... to the number one ranking as a result.  More ... as the most complete and reliable method for clinical ... pain an MRI may confirm a suspected herniated disc ... entirely different treatment protocols.  In these circumstances, patients need ...
Breaking Medicine Technology: